Trial Profile
An Open Label, Partially Randomised Phase II Study to Investigate the Efficacy and Safety of BIBW 2992 in Patients With Metastatic Colorectal Cancer Who Never Received Prior Anti-EGFR (Epidermal Growth Factor Receptor) Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Cetuximab
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 04 Apr 2012 Actual patient number is 94 according to ClinicalTrials.gov.
- 04 Apr 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 04 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.